← All trials
NCT04329611
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 13, 2020
- Primary completion
- Jul 31, 2020
- Completion date
- Aug 31, 2020
- First posted
- Apr 1, 2020
- Last posted
- Apr 15, 2020
- Enrollment
- 1660
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of CalgaryLead sponsor
- University of AlbertaCollaborator
- University of CalgaryCollaborator
- University of CalgarySponsor investigator
- University of CalgaryOverall official - principal investigator
- University of CalgaryStudy director
- Alberta Innovates Health SolutionsCollaborator
- Government of AlbertaCollaborator
- University of CalgaryCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.